Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CytoDyn Inc CYDY

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.


OTCQB:CYDY - Post by User

Bullboard Posts
Post by sunny3999on May 14, 2020 6:03am
142 Views
Post# 31026175

Wow - a must read!

Wow - a must read!
Excerpt: Then there’s Samsung’s biopharmaceutical arm, Samsung Biologics. In the first quarter of this year, ending in March, sales for Samsung Electronics rose 5.6 percent year over year, while sales for Samsung Biologics jumped 65.3 percent. The company also ranked first in March for brand reputation among Korean pharmaceuticals. Last month, it clinched a $362 million deal to make coronavirus antibodies for a U.S. start-up and signed a collaboration deal with Asia’s largest pharmaceutical company, Takeda. Also last month, a Canadian biotech firm reported promising results in treating coronavirus patients with its HIV drug leronlimab, which Samsung Biologics will supply for up to $1 billion over the next few years.
 
https://foreignpolicy.com/2020/05/13/south-korea-pandemic-democracy-chaebol-samsung-corporate-reform/
Bullboard Posts